ENDOCAN TUTHYREF网络一致建议：间变性甲状腺癌。

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Annales d'endocrinologie Pub Date : 2025-05-09 DOI:10.1016/j.ando.2025.101788

Livia Lamartina , Arnaud Jannin , Myriam Decaussin-Petrucci , Stéphane Bardet , Alexandre Escande , Renaud Ciappuccini , Françoise Borson Chazot , Abir Al Ghuzlan , Christine Do Cao , Julien Hadoux

{"title":"ENDOCAN TUTHYREF网络一致建议：间变性甲状腺癌。","authors":"Livia Lamartina , Arnaud Jannin , Myriam Decaussin-Petrucci , Stéphane Bardet , Alexandre Escande , Renaud Ciappuccini , Françoise Borson Chazot , Abir Al Ghuzlan , Christine Do Cao , Julien Hadoux","doi":"10.1016/j.ando.2025.101788","DOIUrl":null,"url":null,"abstract":"<div><div>Anaplastic thyroid cancer is a rare and rapidly deadly disease. In case of clinical suspicion (rapid growth, stony neck mass), diagnostic work-up should be carried out as a matter of urgency to enable prompt treatment. Multidisciplinary assessment involving the patient's referring specialists, the support care team, and if necessary, a geriatric oncology specialist should be performed and must take account of disease extent, comorbidities, general health status and the patient's wishes. Patients and their families should receive realistic information about the prognosis; either active treatment in parallel to support care or exclusive palliative care can be recommended from the outset. Despite the dismal prognosis, recent advances in tumor molecular profiling and treatment with the advent of targeted treatment and immunotherapy hold out great promise for the future. This article summarizes the consensus recommendations on management of anaplastic thyroid cancers by the ENDOCAN TUTHYREF network, a rare-cancer network of the French National Institute for Cancer (INCa).</div></div>","PeriodicalId":7917,"journal":{"name":"Annales d'endocrinologie","volume":"86 4","pages":"Article 101788"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer\",\"authors\":\"Livia Lamartina , Arnaud Jannin , Myriam Decaussin-Petrucci , Stéphane Bardet , Alexandre Escande , Renaud Ciappuccini , Françoise Borson Chazot , Abir Al Ghuzlan , Christine Do Cao , Julien Hadoux\",\"doi\":\"10.1016/j.ando.2025.101788\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Anaplastic thyroid cancer is a rare and rapidly deadly disease. In case of clinical suspicion (rapid growth, stony neck mass), diagnostic work-up should be carried out as a matter of urgency to enable prompt treatment. Multidisciplinary assessment involving the patient's referring specialists, the support care team, and if necessary, a geriatric oncology specialist should be performed and must take account of disease extent, comorbidities, general health status and the patient's wishes. Patients and their families should receive realistic information about the prognosis; either active treatment in parallel to support care or exclusive palliative care can be recommended from the outset. Despite the dismal prognosis, recent advances in tumor molecular profiling and treatment with the advent of targeted treatment and immunotherapy hold out great promise for the future. This article summarizes the consensus recommendations on management of anaplastic thyroid cancers by the ENDOCAN TUTHYREF network, a rare-cancer network of the French National Institute for Cancer (INCa).</div></div>\",\"PeriodicalId\":7917,\"journal\":{\"name\":\"Annales d'endocrinologie\",\"volume\":\"86 4\",\"pages\":\"Article 101788\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales d'endocrinologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0003426625001076\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales d'endocrinologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003426625001076","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

间变性甲状腺癌是一种罕见且迅速致命的疾病。在临床怀疑的情况下（快速生长，石质颈部肿块），诊断检查应作为紧急事项进行，以便及时治疗。应进行多学科评估，包括病人的转诊专家、支助护理小组以及必要时的老年肿瘤学专家，并必须考虑到疾病程度、合并症、一般健康状况和病人的意愿。患者及其家属应获得有关预后的真实信息；从一开始就可以推荐积极治疗与支持性护理并行或单独姑息治疗。尽管预后不佳，但随着靶向治疗和免疫治疗的出现，肿瘤分子分析和治疗的最新进展为未来带来了巨大的希望。本文总结了法国国家癌症研究所（INCa）的罕见癌症网络ENDOCAN - TUTHYREF网络对间变性甲状腺癌治疗的共识建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer

Anaplastic thyroid cancer is a rare and rapidly deadly disease. In case of clinical suspicion (rapid growth, stony neck mass), diagnostic work-up should be carried out as a matter of urgency to enable prompt treatment. Multidisciplinary assessment involving the patient's referring specialists, the support care team, and if necessary, a geriatric oncology specialist should be performed and must take account of disease extent, comorbidities, general health status and the patient's wishes. Patients and their families should receive realistic information about the prognosis; either active treatment in parallel to support care or exclusive palliative care can be recommended from the outset. Despite the dismal prognosis, recent advances in tumor molecular profiling and treatment with the advent of targeted treatment and immunotherapy hold out great promise for the future. This article summarizes the consensus recommendations on management of anaplastic thyroid cancers by the ENDOCAN TUTHYREF network, a rare-cancer network of the French National Institute for Cancer (INCa).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annales d'endocrinologie 医学-内分泌学与代谢

CiteScore

4.40

自引率

6.50%

发文量

311

审稿时长

50 days

期刊介绍： The Annales d''Endocrinologie, mouthpiece of the French Society of Endocrinology (SFE), publishes reviews, articles and case reports coming from clinical, therapeutic and fundamental research in endocrinology and metabolic diseases. Every year, it carries a position paper by a work-group of French-language endocrinologists, on an endocrine pathology chosen by the Society''s Scientific Committee. The journal is also the organ of the Society''s annual Congress, publishing a summary of the symposia, presentations and posters. "Les Must de l''Endocrinologie" is a special booklet brought out for the Congress, with summary articles that are always very well received. And finally, we publish the high-level instructional courses delivered during the Henri-Pierre Klotz International Endocrinology Days. The Annales is a window on the world, keeping alert clinicians up to date on what is going on in diagnosis and treatment in all the areas of our specialty.